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MicroRNAs (miRNA) are important regulators of gene expression.They are involved inmany
physiological processes ensuring the cellular homeostasis of human cells. Alterations of
the miRNA expression have increasingly been associated with pathophysiologic changes
of cancer cells making miRNAs currently to one of the most analyzed molecules in can-
cer research. Here, we provide an overview of miRNAs in lung cancer. Speciﬁcally, we
address biological functions of miRNAs in lung cancer cells, miRNA signatures generated
from tumor tissue and from patients’ body ﬂuids, the potential of miRNAs as diagnostic
and prognostic biomarker for lung cancer, and its role as therapeutic target.
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INTRODUCTION
Besides housekeeping genes, the expression of all other genes is
mostly regulated through a complex mechanism that enables a
cell type speciﬁc and time speciﬁc expression. Regulations can
occur during each step of gene expression, e.g., during chromatin
remodeling, transcription and translation, RNA transport, or on
the post-transcriptional level. Themain gene expression regulators
are proteins or enzymes, e.g., histones, transcription factors, and
polymerases. Gene expression can also be regulated by antisense or
sense nucleic acids (Helene and Toulme, 1990). MicroRNAs (miR-
NAs) are a highly conserved family of small RNAs (17–22 nt) that
regulate the expression of their target genes usually on the post-
transcriptional level by binding to complementary sequences on
target messenger RNA transcripts (mRNAs) mostly resulting in
gene silencing. Since the ﬁrst description of miRNAs in 1993 by
Victor Ambros, Rosalind Lee, and Rhonda Feinbaum in C. elegans
(Lee et al., 1993) more than 1500 different human miRNAs (see
miRBase V18, http://www.mirbase.org) have already been iden-
tiﬁed. As each miRNA can regulate hundreds of target genes, it
is assumed that the majority of the 20,000–25,000 human genes
may be regulated by speciﬁc miRNAs (van Kouwenhove et al.,
2011). Silencing of the target genes is obviously the main regula-
tion mechanism – either by translational repression or by mRNA
degradation. Perfect matching of the miRNA to the 3′ UTR of its
target mRNA results in direct mRNA degradation whereas imper-
fect matching – with nucleotides 2–7 of the miRNA (called “seed
region”) still perfectly complementary – leads to translational
repression. Bartel and colleagues analyzed the relative contribution
of these two outcomes and found that degradation of the mRNA
by miRNAs is with more than 80% of cases the predominant rea-
son for a reduced protein output (Guo et al., 2010). Recently,
miRNAs were also shown to up-regulate target gene expression
either directly through binding to the target mRNA (Vasudevan
et al., 2007) or indirectly through repressing nonsense-mediated
RNA decay (Bruno et al., 2011). According to their function miR-
NAs play an essential role in cellular processes as development,
proliferation, and apoptosis ensuring the cellular homeostasis of
healthy human cells. An alteration of this cellular homeostasis
through aberrant expression of miRNAs likely contributes tomany
human pathologies including cancer. Calin et al. (2002) revealed
for the ﬁrst time a possible correlation between miRNA dereg-
ulation and cancer. Subsequently, a multitude of studies about
miRNA expression changes and cancer has been reported.
Lung cancer is worldwide the leading cause of cancer related
deaths. The 5-year overall survival rate strongly correlates with
the time of diagnosis and varies between 60 and 80% in clinical
stage I to only 1% in clinical stage IV. Unfortunately, lung can-
cer is mostly diagnosed in late stages. Currently, no appropriate
biomarker exists to detect lung cancer at early stages. Takamizawa
et al. (2004) were the ﬁrst to relate miRNA expression to lung
cancer. Since then the number of publications dealing with the
relation between miRNA expression and lung cancer has raised to
above 400.
In this reviewweplace emphasis on the current status of miRNA
research in lung cancer. Speciﬁcally, we focus on current ﬁndings
on the molecular role of miRNAs in lung cancer development
and progression. In addition, we address the potential of miRNA
research for tumor diagnosis and therapy.
DETECTION OF miRNAs IN HUMAN SAMPLES
Most of the miRNA expression data have been generated by the
analysis of tissue samples with themain focus on cancer tissue. The
data collected from tissue samples may provide the best insights
into the involvement of miRNAs in a disease state. As miRNAs are
markedly stable against degradation, stored formalin-ﬁxed paraf-
ﬁn embedded (FFPE) tissue can be used for miRNA isolation (Liu
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and Xu, 2011). Lu et al. (2005) showed that tissue miRNA expres-
sion proﬁles are highly cell type speciﬁc and that they reﬂect
the developmental lineage and the differentiation state. MiRNA
expression data derived from 40 different tissue samples from
healthy individuals revealed both a group of universally expressed
miRNAs and groups of tissue speciﬁc expressed miRNAs (Liang
et al., 2007). Besides tissues, sources for miRNAs can be body
ﬂuids such as whole blood, serum, plasma, urine, cerebrospinal
ﬂuid (CSF), and – especially in the case of lung cancer research –
saliva, sputum, or bronchoalveolar lavage (BAL) (Weber et al.,
2010; Tzimagiorgis et al., 2011). MiRNA proﬁles of body ﬂuids
are useful for the analysis of disease states especially when the dis-
ease does not originate from one distinct type of cell and when
the tissue is not readily accessible, e.g., in neurological disorders
(e.g., Schizophrenia, Lai et al., 2011; Alzheimer’s Disease, Schip-
per et al., 2007), in heart failure (Voellenkle et al., 2010; Meder
et al., 2011), in autoimmune diseases (e.g., Lupus, Wang et al.,
2011), and in respiratory tract diseases (e.g., COPD, Pottelberge
et al., 2011). In general, miRNA proﬁles of body ﬂuids, including
urine (Hanke et al., 2010), serum (Mitchell et al., 2008; Otaegui
et al., 2009), saliva (Park et al., 2009), sputum (Xing et al., 2010),
CSF (Baraniskin et al., 2011) have been discussed as future non-
invasive biomarkers. How miRNAs enter the body ﬂuids is still a
largely unsolved question. One possibility is that cancer cells with-
out metastatic potential enter the blood stream and release their
cell content including miRNAs after passing through a suicide
program (Mehes et al., 2001). Alternatively, miRNAs packed in
microvesicles or exosomes are actively released in the bloodstream
(Hunter et al., 2008; Rabinowits et al., 2009). Notably, miRNAs
measured in body ﬂuids frequently reﬂect different cell types. For
example, urine of a bladder cancer patient contains apoptotic or
necrotic cells, non-malignant exfoliated urothelial cells, and leuko-
cytes besides tumor cells (Hanke et al., 2010), all of which may
contribute to the miRNA expression proﬁle. Saliva contains blood
cells, microorganisms, and apoptotic or detached living epithelial
cells. Cell-free nucleic acids actively released by cancer and epithe-
lial cells or inactively by apoptotic cells and micro-wounds have
also been found in saliva (Park et al., 2006). Likewise, different
cell types contribute to miRNA proﬁles in sputum (Thunnissen,
2003; Xie et al., 2010; Yu et al., 2010), BAL (Ahrendt et al., 1999;
Schmidt et al., 2005), and CSF (Karlsson et al., 2001; Reiber and
Peter, 2001).
In conclusion, the measurement of miRNAs in body ﬂuid has
high potential for future non-invasive diagnostic tests especially
for cancer. There are, however, various hurdles to be overcome
to turn a miRNA signature into a diagnostic tool. Among others,
the amount of speciﬁc miRNAs may be limited in certain body
ﬂuids, the availability of body ﬂuid may also be limited, standard-
ized protocols have not yet been established for the isolation and
analysis of RNA from body ﬂuids, and detection methods have to
be optimized. As for the latter, microarray experiments are both
cost-intensive and time-consuming while qRT-PCR lacks reliable
endogenous controls for body ﬂuids.
THE MOLECULAR BIOLOGY OF miRNAs IN LUNG CANCER
Theﬁrst aberrantly expressedmiRNA in lung cancerwas identiﬁed
in 2004 (Takamizawa et al., 2004). By analyzing 143 potentially
curative resected lung cancer samples Takamizawa et al. (2004)
showed that a reduced let-7 expression is correlated with a shorter
post-operative survival. They conﬁrmed their results by introduc-
ing let-7 into the adenocarcinoma cell line A549. The observed
overexpression resulted in growth inhibition of the cells. These
ﬁndings laid the basis for further studies on the molecular mech-
anisms of the tumor suppressor function of let-7. The 3′ UTR of
HRAS, KRAS, and NRAS that are members of the RAS GTPase
family, contain multiple putative let-7 binding sites. The expres-
sion of let-7 in lung cancer was inversely correlated to RAS expres-
sion. On the basis of these results Johnson et al. (2005) concluded
that let-7 is a negative regulator of the oncogene RAS. Microarray
analysis revealed additional genes whose expressions were altered
in the presence of excess let-7 (Johnson et al., 2007). These genes
include key cell cycle proto-oncogenes such as CDC25a, CDK16,
and cyclin D that are involved in the G1/S transition. These ﬁnd-
ings gave further support to the assumption that let-7 functions
as tumor suppressor miRNA. Recently, let-7 was shown to tar-
get BCL-2, thereby inhibiting the growth of A549 cells (Xiong
et al., 2011). As BCL-2 is a proto-oncogene involved in regula-
tion of apoptosis, a negative regulation through let-7 may result
in growth suppression and apoptosis induction of A549 cells.
Esquela-Kerscher et al. (2008) conﬁrmed that let-7 reduces in vivo
tumor growth of lung cancer cell xenografts in immunodeﬁcient
mice.
Hayashita et al. (2005) found an overexpressed intronic
miRNA cluster (miR-17-92) encompassing seven different miR-
NAs namely hsa-miR-17-5p, hsa-miR-17-3p, hsa-miR-18a, hsa-
miR-19a, hsa-miR-19b-1, hsa-miR-20a, and hsa-miR-92 in the
ampliﬁed chromosomal region 13q31.3 in lung cancer, mostly
in small cell lung cancer. This polycistronic miRNA cluster was
ﬁrst described by He et al. (2005) in B-cell lymphomas. Antisense
oligonucleotides against mir-17-5p and miR-20a were shown to
induce apoptosis in mir-17-92 overexpressing lung cancer cells
(Matsubara et al., 2007). Recently, Kanzaki et al. (2011) were able
to identify several direct targets of the miR-17-92 oncogene. A
summary of the various roles of the miR-17-92 cluster was given
by Joshua T. Mendell in Cell (Mendell, 2008).
Besides hsa-let-7 and the miRNAs of the miR-17-92 cluster,
there are numerous reports on other miRNAs that are deregu-
lated in lung cancer tissue, e.g., hsa-miR-21 whose overexpression
was suggested to be an independent negative prognostic factor for
the overall survival in NSCLC patients (Markou et al., 2008; Gao
et al., 2010). Hsa-miR-21 targets tumor suppressor genes such
as programmed cell death 4 (Pdcd4; Lu et al., 2008) and PTEN
(Zhang et al., 2010). There is evidence that the expression of
miRNA-21 is up regulated by epidermal growth factor receptor
(EGFR)-signaling in lung cancer (Seike et al., 2009). In 15% of
all lung cancer patients, mostly never-smokers, EGFR contained
a mutation resulting in constitutive activation of tyrosine kinase
(TK), which in turn leaded to tumor progression (da Cunha San-
tos et al., 2011). The inhibition of the EGFR signaling by a tyrosine
kinase inhibitor (TKI) resulted in a reduced expression of miR-21
(Seike et al., 2009). But, since miR-21 is also deregulated in sev-
eral other cancer types, it seems to be a general oncogenic miRNA
without tissue speciﬁcity (Ciafre et al., 2005; Volinia et al., 2006;
Iorio et al., 2007; Meng et al., 2007).
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IMPACT OF miRNA RESEARCH ON CLINICAL ONCOLOGY
The 5-year survival of lung cancer patients is 15% for all stages
combined. Early detection of lung cancer in high-risk patients is
likely to improve the prognosis. Currently, less than 20% of lung
cancer patients are diagnosed with a locally conﬁned tumor (Jemal
et al., 2009). This low detection rate calls for the identiﬁcation of
new reliable biomarkers to allow non-invasive early detection of
locally conﬁned lung cancers. The markers should also contribute
to the distinction between benign and malignant lesions.
MicroRNAs play an essential role in lung development
(Tomankova et al., 2010).Due to the different expressionpattern in
healthy lung tissue compared to lung cancer tissue it seemed legit-
imate to assume that aberrant miRNA expression may be involved
in the onset of lung cancer (Mascaux et al., 2009; Megiorni et al.,
2011). By microarray analyses of the miRNA expression in 104
pairs of primary lung cancers and corresponding non-cancerous
lung tissues Yanaihara et al. (2006) identiﬁed a speciﬁc miRNA
proﬁle, encompassing 43 differentially expressed miRNAs. Volinia
et al. (2006) performed a large-scale analysis of the miRNA pro-
ﬁles of 540 samples, encompassing 363 samples from patients with
six different types of solid tumors including lung cancer and 177
normal tissue samples. They identiﬁed a cancer miRNA signature
with mostly overexpressed miRNAs. Besides the identiﬁcation of
cancer type speciﬁc miRNA signatures, research is also aiming at
the identiﬁcationof speciﬁcmiRNAs that are suited to differentiate
between histological lung cancer subclasses. As treatment depends
on the histological subtype, such miRNAs are likely to be useful
for decision-making in clinical treatment. Lebanony et al. (2009)
were able to provide a highly accurate subclassiﬁcation of NSCLC
patients. They identiﬁedmiR-205 as suitablemarker for squamous
cell lung carcinoma by comparing the miRNA expression pat-
tern between 122 adenocarcinoma and squamous NSCLC samples
(Lebanony et al., 2009). MiRNA signatures also appeared suitable
to distinguish SCLC cells from NCLC cells (Du et al., 2010). Vosa
et al. (2011) provided evidence for miR-374 as a potential marker
for early stage NSCLC. Recently, different groups were able to
identify miRNAs that differentiated NSCLC patients with brain
metastases from patients without brain metastases (Arora et al.,
2011; Nasser et al., 2011). Biomarkers that allow identiﬁcation
of NSCLC patients with increased risk for brain metastases will
be of great value for the decision-making in preventive radiation
treatment.
AsmiRNAs are very stable not only in tissue but also in bodyﬂu-
ids, they offer themselves as potential biomarker for non-invasive
early detection of lung cancer. Especially, for lung cancer the poor
survival time and the high relapse rates after surgery call for new
methods to detect the disease at early stage. MiRNA expression
patterns have also the potential to be a useful prognostic tool. In
addition, there is growing interest to use miRNAs as therapeutic
agent. Especially the increasing knowledge about the role of miR-
NAs as tumor suppressors or activators of oncogenes, will help
to develop novel miRNA-based therapeutic approaches. Figure 1
provides an overview about potential different clinical applica-
tions of miRNAs in oncology. Figure 2 gives an overview of the
potential time points for the application of lung cancer speciﬁc
miRNAs. Table A1 in Appendix provides information on miRNAs
associated with lung cancer.
FIGURE 1 |The impact of miRNA research on clinical oncology.
Alterations in miRNA expression are associated with pathophysiological
changes in cancer cells. As miRNA signatures from cancer tissue or
patients’ body ﬂuids differ from those of healthy individuals miRNA
signatures may likely to contribute to improved early diagnosis or patients’
prognosis. Through altered expression single miRNAs may act as oncogene
or they may loose their tumor suppressor properties. Those miRNAs could
be utilized for anti-cancer therapy.
miRNAs AS POTENTIAL DIAGNOSTIC BIOMARKER FOR LUNG CANCER
It is well known that the onset of cancer impacts the immune
system leading to changes in the gene expression of blood cells
(Pardoll, 2003; Kossenkov et al., 2011). Jeong et al. (2011) showed
that the expression of let-7a is reduced not only in lung cancer tis-
sue, but also in blood of lung cancer patients compared to healthy
individuals. In our recent studies, we were able to separate blood
samples of lung cancer patients from blood samples of healthy
individuals by miRNA signatures with a speciﬁcity of 98.1% and
a sensitivity of 92.5% (Keller et al., 2009). In addition we reported
miRNA signatures that differentiated blood samples of lung can-
cer patients from blood samples of patients with non-malignant
chronic obstructive pulmonary disease with 89.2% speciﬁcity, and
91.7% sensitivity (Leidinger et al., 2011). Recently, we showed in
a multicenter study that different types of cancer or non-cancer
diseases could be differentiated by blood-borne miRNA proﬁles
(Keller et al., 2011a).
As above mentioned, miRNAs are also present in other body
ﬂuids. Yu et al. (2010) showed that miRNAs were stably present
in sputum. They were able to differentiate lung adenocarcinoma
patients from healthy individuals by using a panel of four sputum
miRNAs namely miR-486, miR-21, miR-200b, and miR-375, with
high sensitivity (80.6%) and speciﬁcity (91.7%; Yu et al., 2010).
The same group identiﬁed three sputum miRNAs, namely miR-
205,miR-210, and miR-708 that distinguished squamous cell lung
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FIGURE 2 |Time points for the application of lung cancer specific
miRNAs. Speciﬁc tumor-associated miRNA signatures might detect the
tumor prior to CT. After cancer resection and/or therapy (radiotherapy or
chemotherapy) miRNAs might help in therapy monitoring and prognosis.
MiRNAs may also be used for anti-cancer therapy instead of or in combination
with radiotherapy or chemotherapy. The timeline at the bottom of the Figure
shows the growths rate of a lung tumor with several doubling rates (adapted
from Bach et al., 2007).
carcinoma patients from healthy individuals with 73% sensitivity
and 96% speciﬁcity (Xing et al., 2010).
Since the ﬁrst study that demonstrated larger amounts of sta-
ble miRNAs in serum and plasma, several studies proved that
the serum or plasma miRNAs show great promise as novel non-
invasive biomarkers for the early diagnosis of various cancers and
other diseases (Chen et al., 2008; Mitchell et al., 2008). Chen et al.
(2011) identiﬁed in a genome-wide serum miRNA expression
study a speciﬁc panel of 10 miRNAs that was able to distinguish
NSCLC cases from controls with high sensitivity and speciﬁcity
and that correlated with the stage of NSCLC. Furthermore, this
10-serum miRNA proﬁle could accurately classify serum samples
collected up to 3 years prior to the clinical NSCLC diagnosis. By
expression analysis of two serummiRNAs (hsa-miR-1254 and hsa-
miR-574-5p), Foss et al. (2011) were able to discriminate early
stage NSCLC samples from controls with a sensitivity of 82%
and a speciﬁcity of 77% in a training cohort and with a sensi-
tivity of 73% and a speciﬁcity of 71% in a validation cohort. Shen
et al. (2011) recently identiﬁed a panel of four miRNAs namely
miR-21, miR-126, miR-210, and miR-486-5p, that distinguished
NSCLC patients from the healthy controls with 86.22% sensitiv-
ity and 96.55% speciﬁcity. Furthermore, the panel of miRNAs
identiﬁed stage I NSCLC patients with 73.33% sensitivity and
96.55% speciﬁcity. Interestingly, two of these miRNAs, namely
miR-21 and miR-486, show an overlap with the study on spu-
tum by Yu et al. (2010). Rabinowits et al. (2009) investigated
the expression of 12 speciﬁc miRNAs including hsa-miR-17-3p,
hsa-miR-21, hsa-miR-106a, hsa-miR-146, hsa-miR-155, hsa-miR-
191, hsa-miR-192, hsa-miR-203, hsa-miR-205, hsa-miR-210, hsa-
miR-212, and hsa-miR-214, in circulating exosomes. The authors
suggest that circulating exosomal miRNA might be useful in a
screening test for lung adenocarcinoma. In a recent study, we
reported serummiRNAproﬁles as a non-invasivemethod to detect
lung cancer at an early stage (Keller et al., 2011b). We analyzed
miRNA signatures in serum from lung cancer patient samples,
whichwere collected prior and after diagnosis.We found thatmost
obvious changes in miRNA expression proﬁles occur at a time
close to diagnosis possibly indicating increased tumor develop-
ment. Likewise, Boeri et al. (2011) were able to predict lung cancer
in plasma samples 1–2 years prior to diagnosis using CT. For the
time being, however, the source of circulating miRNAs is elusive.
As indicated above it has been suggested that they are released due
to apoptosis or active exocytosis processes (Kosaka et al., 2010).
This hypothesis is supported by the study by Rabinowits et al.
(2009) that showed a similarity between the circulating exosomal
miRNA and the lung tumor-derived miRNA patterns. In contrast,
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miRNAs deregulated in lung cancer tissue were rarely detected in
plasma samples from lung cancer patients in the study of Boeri
et al. (2011) that compared the expression of deregulated miRNAs
in lung cancer tissue with the expression in plasma specimens. To
draw further conclusions about the relationship between miRNA
proﬁles in body ﬂuids and the tumor,more insight is required into
both the exact role of miRNAs as molecular regulators in tumor
cells and the mechanisms underlying the release of miRNA into
body ﬂuids.
miRNAs AS POTENTIAL PROGNOSTIC BIOMARKER FOR LUNG CANCER
Various up- and downregulated miRNAs have been associated
with patients’ survival. Vosa et al. (2011) showed that low expres-
sion of miR-374 could be associated with patients’ low survival
time. Yanaihara et al. (2006) demonstrated that high expression of
hsa-miR-155 and low expression of hsa-let-7a-2 were associated
with lung cancer patients’ poor survival time. Raponi et al. (2009)
showed that miR-146b was associated with reduced survival time
in squamous cell carcinoma tissues (SCC). Recently, a study by
Landi et al. (2010) presented a miRNA signature including let-7e,
miR-34a,miR-34c-5p,miR-25, andmiR-191,whichwas associated
with a prognosis of poor survival among male smokers suffering
from stage I to IIIa SCC. A miR-21 overexpression in NSCLC
that was detected by Markou et al. (2008) has been suggested
as future negative prognostic factor. Hu et al. (2010) analyzed
miRNA expression proﬁles in sera of 303 patients with stage I to
IIIA NSCLC. They detected miRNA levels altered between patients
with shorter survival and longer survival time. Moreover, their
results revealed that four miRNAs, including miR-486, miR-30d,
miR-1, andmiR-499 correlatedwith overall survival. Furthermore,
increased levels of miR-25 andmiR-223 in serummay in the future
serve as potential markers for NSCLC (Chen et al., 2008). By using
microarray, Liu et al. (2011) analyzed the miRNA expression of
six paired lung cancer and normal tissues and identiﬁed three
differentially expressed miRNAs namely miR-21, miR-141, and
miR-200c.High expressions of miR-21 andmiR-200c in the tumor
and of miR-21 in serum were associated with a poor survival in
NSCLC patients (Liu et al., 2011).
Although the above studies clearly show that miRNA expres-
sion can be associated with patients’ survival, the speciﬁc miRNAs
associated with patient survival differ substantially between stud-
ies. These discrepancies are due to (i) different sources of miRNA,
i.e., tissue or body ﬂuid, (ii) different methods applied for miRNA
analysis, i.e., microarray, qRT-PCR, and deep sequencing, (iii)
varying numbers of analyzed miRNAs, and (iv) the criteria used
to select patient cohorts, i.e., ethnicity, clinicopathologic features,
and therapy. Future studies of miRNA signatures should beneﬁt
from largely standardized protocols.
miRNAs AS POTENTIAL THERAPEUTIC AGENT
An increasing number of studies examined the therapeutic poten-
tial of miRNAs. Major emphasis is given to the analysis of hsa-
let-7, which was the ﬁrst miRNA associated with lung cancer
development (Takamizawa et al., 2004; Johnson et al., 2005, 2007).
Exogenous delivery of let-7 inhibited lung cancer growth both
in mouse models and in human lung cancer cell lines (Esquela-
Kerscher et al., 2008; Trang et al., 2010). As for the therapeutic
potential of other miRNAs, a very recent study by Frezzetti et al.
(2011) showed that upregulation of miR-21 is controlled by the
oncogene RAS and that a locked nucleic acid (LNA) against miR-
21 decelerates tumor growth in mice. MiRNA-145 that is known
to function as tumor suppressor in several types of cancer (Akao
et al., 2007; Porkka et al., 2007; Nam et al., 2008) was recently
shown to inhibit cell proliferation in NSCLC cells. Speciﬁcally,
exogenous miRNA-145 inhibited cell proliferation in NSCLC cells
by targeting Myc (Chen et al., 2010). MiR-93, miR-98, and miR-
197 all of which are overexpressed in lung cancer, interact with
the 3′ UTR of the tumor suppressor gene FUS1. This interaction
results in a downregulation of the protein expression making these
miRNAs crucial for tumor progression (Du et al., 2009).MiR-128b
was shown to directly regulate EGFR in NSCLC cell lines. In addi-
tion, loss of heterozygosity of miR-128b was associated with both
the clinical response and patients’ survival (Weiss et al., 2008).
Overexpression of miR-192, which is weakly expressed in lung
cancer, resulted in decreased retinoblastoma 1 (rb1) mRNA and
Rb1 protein expression. These data indicate that miR-192 induces
cell apoptosis through the caspase pathway (Feng et al., 2011).
To fully beneﬁt from the large number of miRNAs and their
potential targets, computational algorithms like PicTar, miRanda,
and Target Scan have been developed to detect adequate miRNA
targets (Sethupathy et al., 2006; Backes et al., 2010). In addi-
tion, suitable delivery systems are being developed to transport
miRNAs or antagomirs – speciﬁc oligomers used as miRNA antag-
onists – to their potential targets (Landen et al., 2005; Shahzad
et al., 2011). Antagomirs have been shown to reduce levels of
corresponding miRNAs in vivo (Krutzfeldt et al., 2005). Using
a lipid-based delivery system and chemically synthesized miR-34a,
Wiggins et al. (2010) demonstrated growth inhibition of subcu-
taneous NSCLC cells in mice. The same group used this delivery
system inKras-activated autochthonousmousemodels of NSCLC.
They found that systemic application of complexes consisting of
synthetic miRNA-mimics for let-7 and miR-34a and of the neu-
tral lipid emulsion are preferentially directed to tumor sites and
signiﬁcantly decreased tumor burden (Trang et al., 2011). Most
recently, a cationic lipid-based miRNA system was used to con-
dense miRNA miR-133b to form lipoplexes in order to enhance
cellular uptake and pharmacological effectiveness in vitro and
in vivo (Wu et al., 2011). As a tumor suppressor that directly tar-
gets the pro-survival gene MCL-1, hsa-miR-133b seems to be a
potential therapeutic target to inﬂuence both cell survival and
sensitivity of lung cancer cells to chemotherapeutic agents (Wu
et al., 2011). Although these examples underline the therapeutic
perspectives of miRNAs, several challenges have to be addressed
on the road toward clinical application. First, delivery systems
without toxic side effects are required to effectively and selec-
tively transport miRNA-based therapeutics to the tumor site. As
of now, lipid-based carrier (Wiggins et al., 2010), nanoparticles
(Shi et al., 2011) or viral delivery systems (Zhang et al., 2006),
have in vitro or in vivo been investigated for cancer therapy. Sec-
ond, the ability of a single miRNA to regulate of up to several
100 targets genes complicates speciﬁc targeting and might readily
result in unspeciﬁc effects. For further information on the ther-
apeutic potential of miRNAs we would like to refer the reader
to the reviews of Kasinski and Slack (2011) in Nature Reviews
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and McDermott et al. (2011) in Pharmaceutical Research, which
provide a comprehensive summary of the current in vivo and/or
in vitro studies.
CONCLUSION
Since their discovery in the 1990s miRNAs have increasingly been
recognized as signiﬁcant not only for the understanding of cancer
growth and progression, but also as potential cancer biomarkers.
Lung cancer as a disease with poor prognosis and a death toll
of thousands of cases per year is one of the prime cancers that
call for new markers to allowing early diagnosis. As summarized
there is considerable progress in developing miRNA signatures
into new biomarkers for lung cancer. MiRNA signatures are likely
to contribute to improved early diagnosis, patients’ prognosis,
or anti-cancer therapy. It is to be, however, recognized, that the
overwhelming majority of studies is still in the ﬁeld of basic sci-
ence and numerous hurdles need to be overcome before any of the
miRNA-based approaches can be introduced in clinical practice.
As for cancer detection, the major challenge will be the implemen-
tation of standardized protocols for the isolation and the analysis
of miRNAs. For cancer therapy, robust and speciﬁc delivery sys-
tems have to be developed for the transport of miRNAs to the
tumor site. Finally, both cancer detection and cancer therapy will
greatly beneﬁt from a better understanding of the biological role
of miRNAs in cancer cells.
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APPENDIX
Table A1 | Summary of miRNAs associated with lung cancer.
miRNA miRNA function in lung neoplasia Reference
hsa-mir-125b-1 Deletion Calin et al. (2004)
hsa-let-7a-1 Reduced expression, decreased abundance; negatively regulate the RAS gene Takamizawa et al. (2004)
hsa-let-7a-2 Reduced expression, decreased abundance; negatively regulate the RAS gene
hsa-let-7a-3 Reduced expression, decreased abundance; negatively regulate the RAS gene
hsa-let-7b Reduced expression, decreased abundance; negatively regulate the RAS gene
hsa-let-7c Reduced expression, decreased abundance; negatively regulate the RAS gene
hsa-let-7d Reduced expression, decreased abundance; negatively regulate the RAS gene
hsa-let-7e Reduced expression, decreased abundance; negatively regulate the RAS gene
hsa-let-7f-1 Reduced expression, decreased abundance; negatively regulate the RAS gene
hsa-let-7f-2 Reduced expression, decreased abundance; negatively regulate the RAS gene
hsa-let-7g Reduced expression, decreased abundance; negatively regulate the RAS gene
hsa-let-7i Reduced expression, decreased abundance; negatively regulate the RAS gene
hsa-mir-17 Overexpressed Hayashita et al. (2005)
hsa-mir-18a Overexpressed
hsa-mir-19a Overexpressed
hsa-mir-19b-1 Overexpressed
hsa-mir-20a Overexpressed
hsa-mir-92a-1 Overexpressed
hsa-mir-128b Overexpressed Volinia et al. (2006)
hsa-mir-155 Overexpressed
hsa-mir-17 Overexpressed
hsa-mir-191 Overexpressed
hsa-mir-199a-1 Overexpressed
hsa-mir-21 Overexpressed
hsa-mir-101-1 Downregulation Yanaihara et al. (2006)
hsa-mir-106a Upregulation
hsa-mir-124a-1 Downregulation
hsa-mir-124a-3 Downregulation
hsa-mir-125a-precursor Downregulation
hsa-mir-125a Downregulation
hsa-mir-126* Downregulation
hsa-mir-126 Downregulation
hsa-mir-140 Downregulation
hsa-mir-143 Downregulation
hsa-mir-145 Downregulation
hsa-mir-146 Upregulation
hsa-mir-150 Upregulation
hsa-mir-155 Upregulation
hsa-mir-17-3p Upregulation
hsa-mir-181c-precursor Downregulation
hsa-mir-191 Upregulation
hsa-mir-192-precursor Downregulation
hsa-mir-192 Upregulation
hsa-mir-197 Upregulaion
hsa-mir-198 Downregulation
hsa-mir-199b-precursor Downregulation
hsa-mir-203 Upregulation
hsa-mir-205 Upregulation
hsa-mir-21 Upregulation
hsa-mir-210 Upregulation
(Continued)
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Table A1 | Continued
miRNA miRNA function in lung neoplasia Reference
hsa-mir-212 Upregulation
hsa-mir-214 Upregulation
hsa-mir-216-precursor Downregulation
hsa-mir-218-2 Downregulation
hsa-mir-219-1 Downregulation
hsa-mir-220 Downregulation
hsa-mir-224 Downregulation
hsa-mir-24-2 Upregulation
hsa-mir-26a-1-precursor Downregulation
hsa-mir-27b Downregulation
hsa-mir-29b-2 Downregulation
hsa-mir-30a-5p Downregulation
hsa-mir-32 Downregulation
hsa-mir-33 Downregulation
hsa-mir-9 Downregulation
hsa-mir-95 Downregulation
hsa-let-7a-2-precursor Downregulation
hsa-mir-132 miR-132, previously shown to be differentially upregulated in six solid cancer types (breast,
colon, lung, pancreas, prostate, and stomach carcinomas)
Lee et al. (2007)
hsa-mir-29a miR-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA
methyltransferases 3A and 3B
Fabbri et al. (2007)
hsa-mir-29b-1 miR-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA
methyltransferases 3A and 3B
hsa-mir-29c miR-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA
methyltransferases 3A and 3B
hsa-mir-128b Increased Weiss et al. (2008)
hsa-mir-126 Inhibits invasion in non-small cell lung carcinoma cell lines Crawford et al. (2008)
hsa-mir-1 Downregulated Nasser et al. (2008)
hsa-mir-183 Potential metastasis-inhibitor Wang et al. (2008)
hsa-let-7a let-7a: A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region
increases non-small cell lung cancer risk
Chin et al. (2008)
hsa-let-7b let-7b: A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region
increases non-small cell lung cancer risk
hsa-let-7d let-7d: A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region
increases non-small cell lung cancer risk
hsa-let-7g let-7g: A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region
increases non-small cell lung cancer risk
hsa-mir-126 Inhibits the growth of lung cancer cell line Liu et al. (2009a)
hsa-mir-142-5p Was repressed, overexpression can inhibit lung cancer growth Liu et al. (2009b)
hsa-mir-145 Was repressed, overexpression can inhibit lung cancer growth
hsa-mir-34c Was repressed, overexpression can inhibit lung cancer growth
hsa-mir-205 Highly speciﬁc marker for squamous cell lung carcinoma Lebanony et al. (2009)
hsa-mir-196a-2 Genetic variant is associated with increased susceptibility of lung cancer in Chinese Tian et al. (2009)
hsa-miR-21 Upregulated in lung cancer in never-smokers Seike et al. (2009)
hsa-mir-141 Upregulated in lung cancer in never-smokers
hsa-mir-210 Upregulated in lung cancer in never-smokers
hsa-mir-200b Upregulated in lung cancer in never-smokers
hsa-mir-346 Upregulated in lung cancer in never-smokers
hsa-mir-126* Downregulated in lung cancer in never-smokers
hsa-mir-126 Downregulated in lung cancer in never-smokers
hsa-mir-30a Downregulated in lung cancer in never-smokers
hsa-mir-30d Downregulated in lung cancer in never-smokers
(Continued)
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Table A1 | Continued
miRNA miRNA function in lung neoplasia Reference
hsa-mir-486 Downregulated in lung cancer in never-smokers
hsa-mir-129 Downregulated in lung cancer in never-smokers
hsa-mir-451 Downregulated in lung cancer in never-smokers
hsa-mir-521 Downregulated in lung cancer in never-smokers
hsa-mir-138 Downregulated in lung cancer in never-smokers
hsa-mir-30b Downregulated in lung cancer in never-smokers
hsa-mir-30c Downregulated in lung cancer in never-smokers
hsa-mir-516a Downregulated in lung cancer in never-smokers
hsa-mir-520 Downregulated in lung cancer in never-smokers
hsa-mir-17-5p miR-17–92 cluster may contribute to protect SCLC cells carrying RB inactivation from excessive
DNA damage and paradoxical growth inhibitory effects, to a large extent by direct
downregulation of E2F1 expression. Overexpression involved in ﬁne-tuning ROS generation
Ebi et al. (2009)
hsa-mir-20a miR-17–92 cluster may contribute to protect SCLC cells carrying RB inactivation from excessive
DNA damage and paradoxical growth inhibitory effects, to a large extent by direct
downregulation of E2F1 expression. Overexpression involved in ﬁne-tuning ROS generation
hsa-mir-145 miR-34c, miR-145, or miR-142-5p expression markedly diminished proliferation of lung cancer
cell lines, clinical implications discussed
Sempere et al. (2009)
hsa-mir-142-5p miR-34c, miR-145, or miR-142-5p expression markedly diminished proliferation of lung cancer
cell lines, clinical implications discussed
hsa-mir-34c miR-34c, miR-145, or miR-142-5p expression markedly diminished proliferation of lung cancer
cell lines, clinical implications discussed
hsa-mir-133b Low expression, targets pro-survival molecules MCL-1 and BCL-2L2 Crawford et al. (2009)
hsa-mir-98 Regulate tumor suppressor gene FUS1 Du et al. (2009)
hsa-mir-197 Regulate tumor suppressor gene FUS1
hsa-mir-93 Regulate tumor suppressor gene FUS1
hsa-mir-185 Cell cycle arrest Takahashi et al. (2009)
hsa-miR-107 Cell cycle arrest
hsa-mir-34a Prognostic marker of relapse in surgically resected non-small cell lung cancer Gallardo et al. (2009)
hsa-let-7g let-7g was downregulated in radio-resistant H1299 cells; increased with response to ionizing
radiation when knockdown LIN28B
Jeong et al. (2009)
hsa-mir-34a miR-34a:MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in
human lung cancer cells
Duan et al. (2010)
hsa-mir-133b Downregulated Navon et al. (2009)
hsa-mir-486-5p Downregulated
hsa-mir-629 Upregulated
hsa-let-7a Inhibition of proliferation in non-small cell lung cancer Zhong et al. (2010)
hsa-mir-126 Inhibition of proliferation in non-small cell lung cancer
hsa-mir-145 Inhibition of proliferation in non-small cell lung cancer
hsa-mir-181b Modulates multidrug resistance by targeting BCL-2 in human cancer cell lines Zhu et al. (2010a)
hsa-mir-486 Levels of four miRNAs (i.e., miR-486, miR-30d, miR-1, and miR-499) were signiﬁcantly
associated with overall survival
Hu et al. (2010)
hsa-mir-30d Levels of four miRNAs (i.e., miR-486, miR-30d, miR-1, and miR-499) were signiﬁcantly
associated with overall survival
hsa-mir-499 Levels of four miRNAs (i.e., miR-486, miR-30d, miR-1, and miR-499) were signiﬁcantly
associated with overall survival
hsa-mir-1 Levels of four miRNAs (i.e., miR-486, miR-30d, miR-1, and miR-499) were signiﬁcantly
associated with overall survival
hsa-mir-21 MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in
non-small cell lung cancer (NSCLC)
Zhang et al. (2010b)
hsa-mir-136 We found that miR-136, miR-376a, and miR-31 were each prominently overexpressed in murine
lung cancers
Liu et al. (2010)
(Continued)
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Table A1 | Continued
miRNA miRNA function in lung neoplasia Reference
hsa-mir-376a We found that miR-136, miR-376a, and miR-31 were each prominently overexpressed in murine
lung cancers
hsa-mir-31 We found that miR-136, miR-376a, and miR-31 were each prominently overexpressed in murine
lung cancers
hsa-mir-182 Suppresses lung tumorigenesis through downregulation of RGS17 expression in vitro Sun et al. (2010)
hsa-mir-148a The silencing of mir-148a production by DNA hypermethylation is an early event in pancreatic
carcinogenesis
Hanoun et al. (2010)
hsa-mir-301a Blocking of miR-301 in A549 cells leads to a decrease in the expression of the host gene, ska2 Cao et al. (2010)
hsa-mir-34a Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34 Wiggins et al. (2010)
hsa-mir-103 Signiﬁcant overexpression of miR-103, miR-107, miR-301, and miR-338 in lung cancer cells as
compared to HBECs
Du et al. (2010)
hsa-mir-107 Signiﬁcant overexpression of miR-103, miR-107, miR-301, and miR-338 in lung cancer cells as
compared to HBECs
hsa-mir-301 Signiﬁcant overexpression of miR-103, miR-107, miR-301, and miR-338 in lung cancer cells as
compared to HBECs
hsa-mir-338 Signiﬁcant overexpression of miR-103, miR-107, miR-301, and miR-338 in lung cancer cells as
compared to HBECs
hsa-mir-186* May serve as a potential gene therapy target for refractory lung cancer that is sensitive to
curcumin
Zhang et al. (2010a)
hsa-mir-206 Associated with invasion and metastasis of lung cancer Wang et al. (2010)
hsa-mir-497 Modulates multidrug resistance of human cancer cell lines by targeting BCL-2 Zhu et al. (2010b)
hsa-mir-145 Inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1 Cho et al. (2011)
hsa-mir-638 Upregulation of mir-638 and mir-923 in bostrycin-treated lung adenocarcinoma cells Chen et al. (2011b)
hsa-mir-923 Upregulation of mir-638 and mir-923 in bostrycin-treated lung adenocarcinoma cells
hsa-mir-34b Suppresses the expression of α4 through speciﬁc binding to the 3′-untranslated region of α4 is
downregulated in transformed or human lung tumors
Chen et al. (2011a)
hsa-let-7a-2 9-cis-RA, all-trans-RA, lithium chloride and CEBPα might play important regulatory roles in let-7a2
gene expression in A549 cells
Guan et al. (2011)
hsa-mir-200 The notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a
miR-200-dependent pathway in mice
Yang et al. (2011)
hsa-mir-9 Enhances the sensitivity to ionizing radiation by suppression of NFKB1 Arora et al. (2011a)
hsa-let-7g Enhances the sensitivity to ionizing radiation by suppression of NFKB1
hsa-let-7g Precursor let-7g microRNA can supress A549 lung cancer cell migration Park et al. (2011)
hsa-mir-145 Suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4 Yin et al. (2011)
hsa-mir-196a-2 hsa-miR-196a2 rs11614913 polymorphism may contribute to the susceptibility of cancers. CC
genotype might modulate lung cancer risk (OR=1.25, 95% CI=1.06–1.46,
pheterogeneity=0.958)
Chu et al. (2011)
hsa-mir-145 Inhibits lung adenocarcinoma stem cells proliferation by targeting OCT4 gene Zhang et al. (2011b)
hsa-mir-182 Inhibits the proliferation and invasion of human lung adenocarcinoma cells through its effect on
human cortical actin-associated protein
Zhang et al. (2011a)
hsa-mir-21 High expression of serum miR-21 associated with poor prognosis in patients with lung cancer Liu et al. (2011)
hsa-mir-200c High expression of tumor miR-200c associated with poor prognosis in patients with lung cancer
hsa-mir-222 High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung
cancer cells.
Zhang et al. (2011c)
hsa-mir-155 Could signiﬁcantly inhibit the growth of human lung cancer 95D cells in vitro, which might be
closely related to miR-155 induced G0/G1 phase arrest
Qin et al. (2011)
(Continued)
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Table A1 | Continued
miRNA miRNA function in lung neoplasia Reference
hsa-mir-125a-5p Induces apoptosis by activating p53 in lung cancer cells Jiang et al. (2011)
hsa-mir-146b Overexpression of the Lung Cancer-prognostic miR-146b has a minimal and negative effect on
the malignant phenotype of A549 Lung cancer cells
Patnaik et al. (2011)
hsa-mir-101 miR-101 DNA copy loss is a prominent subtype speciﬁc event in lung cancer Thu et al. (2011)
hsa-mir-375 miR-375 is activated by ASH1 and inhibits YAP1 in a lineage dependent manner in lung cancer Nishikawa et al. (2011)
hsa-mir-26b Expression of miR-26b was downregulated, and its target activating transcription factor 2 (ATF2)
mRNA was up regulated in γ-irradiated H1299 cells
Arora et al. (2011b)
hsa-mir-155 The levels of miR-155, miR-197, and miR-182 in the plasma of lung cancer including stage I
patients were signiﬁcantly elevated compared with controls (P <0.001). The combination of
these three miRNAs yielded 81.33% sensitivity and 86.76% speciﬁcity in discriminating lung
cancer patients from controls. The levels of miR-155 and miR-197 were higher in the plasma
from lung cancer patients with metastasis than in those without metastasis (P <0.05) and were
signiﬁcantly decreased in responsive patients during chemotherapy (P <0.001)
Zheng et al. (2011)
hsa-mir-197 The levels of miR-155, miR-197, and miR-182 in the plasma of lung cancer including stage I
patients were signiﬁcantly elevated compared with controls (P <0.001). The combination of
these three miRNAs yielded 81.33% sensitivity and 86.76% speciﬁcity in discriminating lung
cancer patients from controls. The levels of miR-155 and miR-197 were higher in the plasma
from lung cancer patients with metastasis than in those without metastasis (P <0.05) and were
signiﬁcantly decreased in responsive patients during chemotherapy (P <0.001)
hsa-mir-182 The levels of miR-155, miR-197, and miR-182 in the plasma of lung cancer including stage I
patients were signiﬁcantly elevated compared with controls (P <0.001). The combination of
these three miRNAs yielded 81.33% sensitivity and 86.76% speciﬁcity in discriminating lung
cancer patients from controls. The levels of miR-155 and miR-197 were higher in the plasma
from lung cancer patients with metastasis than in those without metastasis (P <0.05) and were
signiﬁcantly decreased in responsive patients during chemotherapy (P <0.001)
hsa-mir-183 Expression levels of members of the miR-183 family in lung cancer tumor and sera were higher
than that of their normal counterparts. The miR-96 expression in tumors was positively
associated with its expression in sera. High expression of tumor and serum miRNAs of the
miR-183 family were associated with overall poor survival in patients with lung cancer
Zhu et al. (2011)
hsa-mir-96 Expression levels of members of the miR-183 family in lung cancer tumor and sera were higher
than that of their normal counterparts. The miR-96 expression in tumors was positively
associated with its expression in sera. High expression of tumor and serum miRNAs of the
miR-183 family were associated with overall poor survival in patients with lung cancer
hsa-mir-150 Anti-miR-150 vector can regress A549 lung cancer tumors Li et al. (2011)
hsa-mir-200b Stably expressing microRNA-200b in As-p53lowHBECs (human bronchial epithelial cell)
abolished Akt and Erk1/2 activation, and completely suppressed cell migration and invasion
Wang et al. (2011b)
hsa-mir-9 Upregulated in NSCLC compared to non-tumorous tissue Vosa et al. (2011)
hsa-mir-182 Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-200a+ Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-151 Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-205 Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-183 Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-130b* Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-149 Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-193b Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-339-5p Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-196b Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-224 Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-31 Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-196a Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-423-3p Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-708 Upregulated in NSCLC compared to non-tumorous tissue
(Continued)
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Table A1 | Continued
miRNA miRNA function in lung neoplasia Reference
hsa-mir-106b* Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-210 Upregulated in NSCLC compared to non-tumorous tissue
hsa-mir-1273 Downregulated in NSCLC compared to non-tumorous tissue
hsa-mir-206 Downregulated in NSCLC compared to non-tumorous tissue
hsa-mir-140-3p Downregulated in NSCLC compared to non-tumorous tissue
hsa-mir-338-3p Downregulated in NSCLC compared to non-tumorous tissue
hsa-mir-101 Downregulated in NSCLC compared to non-tumorous tissue
hsa-mir-144 Downregulated in NSCLC compared to non-tumorous tissue
hsa-mir-1285 Downregulated in NSCLC compared to non-tumorous tissue
hsa-mir-130a Downregulated in NSCLC compared to non-tumorous tissue
hsa-mir-486-5p Downregulated in NSCLC compared to non-tumorous tissue
hsa-mir-24-2* Downregulated in NSCLC compared to non-tumorous tissue
hsa-mir-144* Downregulated in NSCLC compared to non-tumorous tissue
hsa-mir-30a Downregulated in NSCLC compared to non-tumorous tissue
hsa-mir-20a Upregulated in NSCLC serum compared to control serum Chen et al. (2011c)
hsa-mir-24 Upregulated in NSCLC serum compared to control serum
hsa-mir-25 Upregulated in NSCLC serum compared to control serum
hsa-mir-145 Upregulated in NSCLC serum compared to control serum
hsa-mir-152 Upregulated in NSCLC serum compared to control serum
hsa-mir-199a-5p Upregulated in NSCLC serum compared to control serum
hsa-mir-221 Upregulated in NSCLC serum compared to control serum
hsa-mir-222 Upregulated in NSCLC serum compared to control serum
hsa-mir-223 Upregulated in NSCLC serum compared to control serum
hsa-mir-320 Upregulated in NSCLC serum compared to control serum
hsa-mir-126 Upregulated in radiotherapy sensitive patients compared to resistant patients of non-small cell
lung cancer
Wang et al. (2011a)
hsa-mir-let-7a Upregulated in radiotherapy sensitive patients compared to resistant patients of non-small cell
lung cancer
hsa-mir-495 Upregulated in radiotherapy sensitive patients compared to resistant patients of non-small cell
lung cancer
hsa-mir-451 Upregulated in radiotherapy sensitive patients compared to resistant patients of non-small cell
lung cancer
hsa-mir-128b Upregulated in radiotherapy sensitive patients compared to resistant patients of non-small cell
lung cancer
hsa-mir-130a Downregulated in radiotherapy sensitive patients compared to resistant patients of non-small
cell lung cancer
hsa-mir-106b Downregulated in radiotherapy sensitive patients compared to resistant patients of non-small
cell lung cancer
hsa-mir-19b Downregulated in radiotherapy sensitive patients compared to resistant patients of non-small
cell lung cancer
hsa-mir-22 Downregulated in radiotherapy sensitive patients compared to resistant patients of non-small
cell lung cancer
hsa-mir-15b Downregulated in radiotherapy sensitive patients compared to resistant patients of non-small
cell lung cancer
hsa-mir-17-5p Downregulated in radiotherapy sensitive patients compared to resistant patients of non-small
cell lung cancer
hsa-mir-21 Downregulated in radiotherapy sensitive patients compared to resistant patients of non-small
cell lung cancer
hsa-miR-126 Downregulated in lung SCC compared to normal lung tissues Yang et al. (2010)
hsa-miR-193a-3p Downregulated in lung SCC compared to normal lung tissues
hsa-miR-30d Downregulated in lung SCC compared to normal lung tissues
hsa-miR-30a Downregulated in lung SCC compared to normal lung tissues
(Continued)
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Table A1 | Continued
miRNA miRNA function in lung neoplasia Reference
hsa-miR-101 Downregulated in lung SCC compared to normal lung tissues
hsa-let-7i Downregulated in lung SCC compared to normal lung tissues
hsa-miR-15a Downregulated in lung SCC compared to normal lung tissues
hsa-miR-185 * Upregulated in lung SCC compared to normal lung tissues
hsa-miR-125a-5p Upregulated in lung SCC compared to normal lung tissues
hsa-let-7f Decreased in plasma vesicles from 28 NSCLC patients and 20 controls. Plasma levels of
mir-30e-3p and let-7f were associated with short disease-free survival and overall survival
Silva et al. (2011)
hsa-miR-20b Decreased in plasma vesicles from 28 NSCLC patients and 20 controls
hsa-miR-30e-3p Decreased in plasma vesicles from 28 NSCLC patients and 20 controls. Plasma levels of
mir-30e-3p and let-7f were associated with short disease-free survival and overall survival
hsa-miR-21 Overexpressed in cell lines for breast cancer, prostate cancer, glioblastoma, and lung cancer Roa et al. (2010)
hsa-miR-182 Overexpressed in cell lines for breast cancer, prostate cancer, glioblastoma, and lung cancer
hsa-let-7-5a Underexpressed in cell lines for breast cancer, prostate cancer, glioblastoma, and lung cancer
hsa-miR-145 Underexpressed in cell lines for breast cancer, prostate cancer, glioblastoma, and lung cancer
hsa-miR-155
hsa-miR-21 Upregulated in lung carcinoma tissues and their corresponding normal lung tissues, high mir-21
expression and low mir-181a expression were associated with poor survival, independent of
clinical covariates, includingTNM staging, lymph note status
Gao et al. (2010)
hsa-mir-143 Downregulated in lung carcinoma tissues and their corresponding normal lung tissues, low level
expression of mir-143 was signiﬁcantly correlated with smoking status
hsa-mir-181a Downregulated in lung carcinoma tissues and their corresponding normal lung tissues, high
mir-21 expression and low mir-181a expression were associated with poor survival, independent
of clinical covariates, includingTNM staging, lymph note status
hsa-let-7g Upregulated in adenocarcinoma compared to squamous cell carcinoma Landi et al. (2010)
hsa-let-7b Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-let-7c Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-29a Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-let-7f Upregulated in adenocarcinoma compared to squamous cell carcinoma
has-miR-453 Downregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-let-7d Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-98 Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-let-7i Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-26a Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-509-3p Downregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-30b Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-146b-5p Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-106b Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-let-7a Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-mir-663 Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-30d Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-17 Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-498 Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-26b Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-let-7e Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-mir-654-5p Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-181a Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-103 Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-195 Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-191 Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-20a Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-106a Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-29c Upregulated in adenocarcinoma compared to squamous cell carcinoma
(Continued)
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miRNA miRNA function in lung neoplasia Reference
hsa-miR-29b Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-491-5p Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-19b Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-107 Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-miR-16 Upregulated in adenocarcinoma compared to squamous cell carcinoma
hsa-mir-129-5p Underexpressed in recurrence vs. No recurrence case groups of stage I NSCLC Patnaik et al. (2010)
hsa-mir-194 Underexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-631 Underexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-200b Underexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-585 Underexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-623 Underexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-617 Underexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-622 Underexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-638 Underexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-24 Overexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-141 Overexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-27b Overexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-16 Overexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-21 Overexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-30c Overexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-106a Overexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-15b Overexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-23b Overexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-23b Overexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-130a Overexpressed in recurrence vs. No recurrence case groups of stage I NSCLC
hsa-mir-636 Changed more than twofold by radiation doses of 20Gy Shin et al. (2009)
hsa-mir-593 Changed more than twofold by radiation doses of 20Gy
hsa-mir-760 Changed more than twofold by radiation doses of 20Gy
hsa-mir-139-3p Changed more than twofold by radiation doses of 20Gy
hsa-mir-345 Changed more than twofold by radiation doses of 20Gy and 40Gy
hsa-mir-885-3p Changed more than twofold by radiation doses of 20Gy and 40Gy
hsa-mir-206 Changed more than twofold by radiation doses of 20Gy and 40Gy
hsa-mir-516a-5p Changed more than twofold by radiation doses of 20Gy and 40Gy
hsa-mir-16-2* Changed more than twofold by radiation doses of 20Gy and 40Gy
hsa-mir-106a Changed more than twofold by radiation doses of 20Gy and 40Gy
hsa-mir-548c-3p Changed more than twofold by radiation doses of 20Gy and 40Gy
hsa-mir-127-3p Changed more than twofold by radiation doses of 20Gy and 40Gy
hsa-mir-1228* Changed more than twofold by radiation doses of 40Gy
hsa-mir-30b* Changed more than twofold by radiation doses of 40Gy
hsa-mir-376a Changed more than twofold by radiation doses of 40Gy
hsa-mir-34b* Changed more than twofold by radiation doses of 40Gy
hsa-mir-215 Changed more than twofold by radiation doses of 40Gy
hsa-mir-183 Changed more than twofold by radiation doses of 40Gy
hsa-mir-22* Changed more than twofold by radiation doses of 40Gy
hsa-mir-34a Changed more than twofold by radiation doses of 40Gy
hsa-mir-192 Changed more than twofold by radiation doses of 40Gy
hsa-mir-30c-1* Changed more than twofold by radiation doses of 40Gy
hsa-mir-21 Mir-21 expression in the sputum specimens was signiﬁcantly higher in cancer patients than
cancer-free individuals. overexpression of mir-21 showed highly discriminative receiver-operator
characteristic (ROC) curve proﬁle, clearly distinguishing cancer patients from cancer-free subjects
Detection of mir-21 expression produced 69.66% sensitivity and 100.00% speciﬁcity in diagnosis
of lung cancer, as compared with 47.82% sensitivity and 100.00% speciﬁcity by sputum cytology
Xie et al. (2010)
(Continued)
www.frontiersin.org January 2012 | Volume 2 | Article 104 | 17
Leidinger et al. MicroRNAs in lung cancer research
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miRNA miRNA function in lung neoplasia Reference
hsa-mir-140-3p Expression of 13 miRNA genes predicts response to EGFR inhibition in cancer cell lines and
tumors, and discriminates primary from metastatic tumors
Bryant et al. (2011)
hsa-mir-628-5p Expression of 13 miRNA genes predicts response to EGFR inhibition in cancer cell lines and
tumors, and discriminates primary from metastatic tumors
hsa-mir-518f Expression of 13 miRNA genes predicts response to EGFR inhibition in cancer cell lines and
tumors, and discriminates primary from metastatic tumors
hsa-mir-636 Expression of 13 miRNA genes predicts response to EGFR inhibition in cancer cell lines and
tumors, and discriminates primary from metastatic tumors
hsa-mir-301a Expression of 13 miRNA genes predicts response to EGFR inhibition in cancer cell lines and
tumors, and discriminates primary from metastatic tumors
hsa-mir-34c Expression of 13 miRNA genes predicts response to EGFR inhibition in cancer cell lines and
tumors, and discriminates primary from metastatic tumors
hsa-mir-224 Expression of 13 miRNA genes predicts response to EGFR inhibition in cancer cell lines and
tumors, and discriminates primary from metastatic tumors
hsa-mir-197 Expression of 13 miRNA genes predicts response to EGFR inhibition in cancer cell lines and
tumors, and discriminates primary from metastatic tumors
hsa-mir-205 Expression of 13 miRNA genes predicts response to EGFR inhibition in cancer cell lines and
tumors, and discriminates primary from metastatic tumors
hsa-mir-135b Expression of 13 miRNA genes predicts response to EGFR inhibition in cancer cell lines and
tumors, and discriminates primary from metastatic tumors
hsa-mir-200b Expression of 13 miRNA genes predicts response to EGFR inhibition in cancer cell lines and
tumors, and discriminates primary from metastatic tumors
hsa-mir-200c Expression of 13 miRNA genes predicts response to EGFR inhibition in cancer cell lines and
tumors, and discriminates primary from metastatic tumors
hsa-mir-141 Expression of 13 miRNA genes predicts response to EGFR inhibition in cancer cell lines and
tumors, and discriminates primary from metastatic tumors
hsa-mir-182 Overexpressed in primary lung tumors vs. metastases to lung Barshack et al. (2010)
hsa-mir-126 Underexpressed in primary lung tumors vs. metastases to lung
hsa-mir-200c Overexpressed in primary lung tumors vs. metastases to lung
hsa-mir-141 Overexpressed in primary lung tumors vs. metastases to lung
hsa-mir-375 Overexpressed in primary lung tumors vs. metastases to lung
hsa-mir-7 Overexpressed in primary lung tumors vs. metastases to lung
hsa-mir-429 Overexpressed in primary lung tumors vs. metastases to lung
hsa-mir-200a Overexpressed in primary lung tumors vs. metastases to lung
hsa-mir-370 Overexpressed in primary lung tumors vs. metastases to lung
hsa-mir-451 Underexpressed in primary lung tumors vs. metastases to lung
hsa-mir-195 Underexpressed in primary lung tumors vs. metastases to lung
hsa-mir-200b Overexpressed in primary lung tumors vs. metastases to lung
hsa-mir-486-5p Underexpressed in primary lung tumors vs. metastases to lung
hsa-mir-214 Underexpressed in primary lung tumors vs. metastases to lung
hsa-mir-382 Overexpressed in primary lung tumors vs. metastases to lung
hsa-mir-199a-5p Underexpressed in primary lung tumors vs. metastases to lung
hsa-mis-210 Upregulated in lung SCC compared to normal tissue Raponi et al. (2009)
hsa-mir-200c Upregulated in lung SCC compared to normal tissue
hsa-mir-17-5p Upregulated in lung SCC compared to normal tissue
hsa-mir-20a Upregulated in lung SCC compared to normal tissue
hsa-mir-203 Upregulated in lung SCC compared to normal tissue
hsa-mir-125a Downregulated in lung SCC compared to normal tissue
hsa-let-7e Downregulated in lung SCC compared to normal tissue
hsa-mir-200a Upregulated in lung SCC compared to normal tissue
hsa-mir-106b Upregulated in lung SCC compared to normal tissue
hsa-mir-93 Upregulated in lung SCC compared to normal tissue
(Continued)
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miRNA miRNA function in lung neoplasia Reference
hsa-mir-182 Upregulated in lung SCC compared to normal tissue
hsa-mir-183 Upregulated in lung SCC compared to normal tissue
hsa-mir-106a Upregulated in lung SCC compared to normal tissue
hsa-mir-20b Upregulated in lung SCC compared to normal tissue
hsa-mir-224 Upregulated in lung SCC compared to normal tissue
hsa-miR-126 Downregulated in NSCLC blood compared to normal blood Keller et al. (2009)
hsa-miR-423-5p Upregulated in NSCLC blood compared to normal blood
hsa-let-7d Downregulated in NSCLC blood compared to normal blood
hsa-let-7i Downregulated in NSCLC blood compared to normal blood
hsa-miR-15a Downregulated in NSCLC blood compared to normal blood
hsa-miR-22 Upregulated in NSCLC blood compared to normal blood
hsa-miR-98 Downregulated in NSCLC blood compared to normal blood
hsa-miR-19a Upregulated in NSCLC blood compared to normal blood
hsa-miR-20b Downregulated in NSCLC blood compared to normal blood
hsa-miR-324-3p Upregulated in NSCLC blood compared to normal blood
hsa-miR-574-5p Upregulated in NSCLC blood compared to normal blood
hsa-miR-195 Downregulated in NSCLC blood compared to normal blood
hsa-miR-25 Upregulated in NSCLC blood compared to normal blood
hsa-let-7e Downregulated in NSCLC blood compared to normal blood
hsa-let-7c Downregulated in NSCLC blood compared to normal blood
hsa-let-7f Downregulated in NSCLC blood compared to normal blood
hsa-let-7a Downregulated in NSCLC blood compared to normal blood
hsa-let-7g Downregulated in NSCLC blood compared to normal blood
hsa-miR-140-3p Upregulated in NSCLC blood compared to normal blood
hsa-miR-339-5p Upregulated in NSCLC blood compared to normal blood
hsa-miR-361-5p Upregulated in NSCLC blood compared to normal blood
hsa-miR-1283 Downregulated in NSCLC blood compared to normal blood
hsa-miR-18a* Upregulated in NSCLC blood compared to normal blood
hsa-miR-26b Downregulated in NSCLC blood compared to normal blood
hsa-miR-641 Downregulated in lung cancer vs. COPD Leidinger et al. (2011)
hsa-miR-662 Upregulated in lung cancer vs. COPD
hsa-miR-369-5p Downregulated in lung cancer vs. COPD
hsa-miR-383 Downregulated in lung cancer vs. COPD
hsa-miR-636 Upregulated in lung cancer vs. COPD
hsa-miR-940 Upregulated in lung cancer vs. COPD
hsa-miR-26a Downregulated in lung cancer vs. COPD
hsa-miR-92a Upregulated in lung cancer vs. COPD
hsa-miR-328 Upregulated in lung cancer vs. COPD
hsa-let-7d* Upregulated in lung cancer vs. COPD
hsa-miR-1224-3p Upregulated in lung cancer vs. COPD
hsa-miR-513b Downregulated in lung cancer vs. COPD
hsa-miR-93* Upregulated in lung cancer vs. COPD
hsa-miR-675 Upregulated in lung cancer vs. COPD
This table only includes a selection of available publications.
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